Discovery of Novel Broad-Spectrum Coronavirus Mpro Inhibitors

NIH RePORTER · NIH · U19 · $2,770,981 · view on reporter.nih.gov ↗

Abstract

PROJECT 1 - ABSTRACT The goal of this project is to discover novel broad-spectrum coronavirus main protease (Mpro) inhibitors. We have already obtained promising first-generation Mpro inhibitors with desired potency and drug-like properties. The first-generation Mpro inhibitors are rapidly progressing to clinical development. In the current application, we will capitalize the success of the first-generation inhibitor to develop the second-generation inhibitor. In anticipation of future coronavirus emergence, the second-generation inhibitor will have (i) activities against viruses resistant to the first-generation inhibitor and (ii) a broader coverage against different coronaviruses. To achieve this goal, we will pursue three aims: (i) identify the antiviral spectrum of the first-generation Mpro inhibitor and evaluate the potential to induce resistance; (ii) discover and optimize a second-generation novel broad- spectrum Mpro inhibitor to anticipate potential resistance and future pandemics; and (iii) advance our second- generation broad-spectrum coronavirus Mpro inhibitor through preclinical development to deliver an IND-ready clinical candidate.

Key facts

NIH application ID
10514152
Project number
1U19AI171413-01
Recipient
UNIVERSITY OF TEXAS MED BR GALVESTON
Principal Investigator
Julien Papillon
Activity code
U19
Funding institute
NIH
Fiscal year
2022
Award amount
$2,770,981
Award type
1
Project period
2022-05-16 → 2025-03-24